8-K filing — PULSE BIOSCIENCES, INC. (PLSE)
Filed: 2026-10-14 AccNo: 0001437749-26-032601 Size: 171 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Filings · News reference
Pulse Biosciences Files Prospectus Supplement For Up To $85M At-The-market Common Stock Offering Via Mizuho; Terminates TD Cowen Distribution Agreement On Sept 14, 2026 With $1M Unsold
On September 15, 2026, Pulse Biosciences, Inc. (the "Company") entered into an equity distribution agreement (the "Sales Agreement") with Mizuho Securities USA LLC ("Mizuho") as sales agent,
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Pulse Biosciences Partners With Clayman Thyroid Center At Hospital For Endocrine Surgery In Tampa, Florida
Collaboration adds the nPulse™ Vybrance™ System to patient care at the Hospital for Endocrine Surgery and supports generation of additional clinical dataPulse Biosciences, Inc. (NASDAQ:PLSE), the company leveraging its
Oppenheimer Maintains Outperform on Pulse Biosciences, Raises Price Target to $60
Oppenheimer analyst Suraj Kalia maintains Pulse Biosciences (NASDAQ:PLSE) with a Outperform and raises the price target from $35 to $60.
Pulse Biosciences Announces Completion Of 164-Patient Enrollment In Pivotal Atrial Fibrillation Study Of nPulse Catheter, Three Months Ahead Of Schedule